Please login to the form below

Not currently logged in

Pfizer India selects Aijaz Tobaccowalla as managing director

He will take over from Kewal Handa, who retires in August

Pfizer has appointed Aijaz Tobaccowalla to lead its Mumbai-headquartered Indian operations, taking over from Kewal Handa who will retire in August.

Tobaccowalla has more than 20 years' experience in the pharma industry, almost all of them spent at either Pfizer or Wyeth, which Pfizer acquired in 2009.

Ahmet Goksun, regional president of Pfizer's Emerging Markets Europe, Russia, India and Turkey (EURIT) unit, said: “Aijaz, 'Jazz', is a seasoned leader who will continue to lead Pfizer India through this exciting period. His leadership experience, demonstrated versatility, and successful management in a constantly changing business environment, make him the ideal leader for Pfizer India.

“We thank Kewal for his many contributions at Pfizer. Under his leadership, Pfizer India became the first multi-national pharmaceutical company to enter the branded generics market, and became a leader in exploring unique partnerships with the government to increase market access.”

Tobaccowalla joined Wyeth in 1991 and held a number of business technology positions before joining leadership teams within Pfizer.

In 2009 he was appointed to his present role to lead the company's business technology function for all of its biopharmaceutical business units.

Pfizer employs over 2,300 people in India and in addition to its Mumbai HQ the company also has a manufacturing facility at Thane in Maharashtra.

2nd July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018